BRIM Biotechnology, Inc. (TPEX: 6885)
Taiwan
· Delayed Price · Currency is TWD 42.65
+0.35 (0.83%)
Nov 20, 2024, 2:58 PM CST
BRIM Biotechnology Income Statement
Financials in millions TWD. Fiscal year is January - December.
Millions TWD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|
Period Ending | Sep '24 Sep 30, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 |
| Revenue | 0.11 | 0.09 | 0.53 | 0.36 | 90.77 | - |
| Revenue Growth (YoY) | -63.96% | -82.89% | 46.11% | -99.60% | - | - |
| Gross Profit | 0.05 | 0.09 | 0.53 | 0.36 | 90.77 | - |
| Selling, General & Admin | 99.61 | 112.33 | 72.96 | 44.97 | 40.36 | 39.79 |
| Research & Development | 389.58 | 581.88 | 145.89 | 48.6 | 205.81 | 85.26 |
| Operating Expenses | 489.19 | 694.22 | 218.85 | 93.58 | 246.17 | 125.05 |
| Operating Income | -489.14 | -694.13 | -218.33 | -93.22 | -155.4 | -125.05 |
| Interest Expense | -0.08 | -0.15 | -0.08 | -0.11 | -0.07 | -0.12 |
| Interest & Investment Income | 32.76 | 21.8 | 0.83 | 0.5 | 1.34 | 2 |
| Earnings From Equity Investments | -21.61 | -24.59 | -62.62 | -47.94 | -9.66 | - |
| Currency Exchange Gain (Loss) | 0.86 | 9.03 | 5.9 | -1.76 | -10.25 | 0.69 |
| Other Non Operating Income (Expenses) | 10.56 | 0 | 0.02 | 4.21 | 1.47 | 0.48 |
| EBT Excluding Unusual Items | -466.63 | -688.04 | -274.28 | -138.32 | -172.57 | -122.01 |
| Gain (Loss) on Sale of Investments | - | - | - | - | 26.77 | - |
| Gain (Loss) on Sale of Assets | 0.01 | 0.01 | - | 32.87 | 48.79 | - |
| Pretax Income | -466.63 | -688.02 | -274.28 | -105.45 | -97.01 | -122.01 |
| Income Tax Expense | - | - | - | - | 9.14 | - |
| Earnings From Continuing Operations | -466.63 | -688.02 | -274.28 | -105.45 | -106.15 | -122.01 |
| Minority Interest in Earnings | - | - | - | - | 18.21 | 3.24 |
| Net Income | -466.63 | -688.02 | -274.28 | -105.45 | -87.94 | -118.77 |
| Net Income to Common | -466.63 | -688.02 | -274.28 | -105.45 | -87.94 | -118.77 |
| Shares Outstanding (Basic) | 114 | 101 | 71 | 59 | 59 | 59 |
| Shares Outstanding (Diluted) | 114 | 101 | 71 | 59 | 59 | 59 |
| Shares Change (YoY) | 23.87% | 41.02% | 20.23% | 0.72% | 0.16% | - |
| EPS (Basic) | -4.10 | -6.84 | -3.85 | -1.78 | -1.49 | -2.02 |
| EPS (Diluted) | -4.10 | -6.84 | -3.85 | -1.78 | -1.49 | -2.02 |
| Free Cash Flow | -427 | -599.15 | -172.98 | -113.35 | -127.48 | -114.13 |
| Free Cash Flow Per Share | -3.75 | -5.96 | -2.43 | -1.91 | -2.17 | -1.94 |
| Gross Margin | 45.95% | 100.00% | 100.00% | 100.00% | 100.00% | - |
| Operating Margin | -440664.86% | -771250.00% | -41506.84% | -25893.06% | -171.21% | - |
| Profit Margin | -420384.68% | -764468.89% | -52143.92% | -29291.39% | -96.89% | - |
| Free Cash Flow Margin | -384684.23% | -665723.33% | -32885.74% | -31485.83% | -140.45% | - |
| EBITDA | -483.95 | -692.92 | -218.02 | -93.01 | -155.08 | -123.61 |
| EBITDA Margin | - | - | - | - | -170.86% | - |
| D&A For EBITDA | 5.19 | 1.2 | 0.31 | 0.2 | 0.32 | 1.44 |
| EBIT | -489.14 | -694.13 | -218.33 | -93.22 | -155.4 | -125.05 |
| EBIT Margin | - | - | - | - | -171.21% | - |
Source: S&P Capital IQ. Standard template. Financial Sources.